AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Why Membrane Matters In AAV Filtration
Gene therapy is revolutionizing medicine to offer one-time treatments. Find out how AAV vectors are leading the way to optimize production and make these life-changing therapies accessible.
-
Scaling Of Impingement Jets Mixing For LNP Drug Production
Delve into the intricacies of Impingement Jets Mixing (IJM) technology and its pivotal role in the scalable and reproducible production of Lipid Nanoparticles (LNPs) for drug delivery.
-
Accelerating Clinical Data Review With Traceable Workflows
Clinical data review needs centralized access and traceable workflows. Leveraging AI-automation and real-time collaboration drives faster, better-informed decisions and reduced compliance risk.
-
Challenges And Solution In The Poly (A) Control For Plasmid And mRNA
Poly(A) tail integrity is critical for mRNA stability and translation. Advanced strategies optimize plasmid design, transcription, and purification to ensure consistent poly(A) control for therapeutic success.
-
Simplify Your Bioprocess Development With Custom Buffers
Tailor your bioprocess for optimal cell growth, gene expression, and therapeutic production with custom buffers to ensure precise control over pH, ion concentrations, and nutrient availability.
-
Partner Case Study: Accelerating Gene Editing Manufacturing
Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.
-
Navigating Patient Access Challenges In Commercializing Your CGT Product
Learn how to effectively break down barriers to patient access in cell and gene therapy by enhancing provider education, streamlining coordination, and expanding patient support.
-
Producing MSC-Derived Cell Therapies From Isolation To Large-Scale Expansion
Explore the journey of producing MSC-derived cell therapies, from initial isolation and expansion to final product formulation and storage, and learn how to optimize each step.
-
The Unique Challenges Of The Cell & Gene Therapy Supply Chain
Cell and gene therapies present unique logistical challenges for the supply chain, requiring careful consideration of factors like shelf life, packaging, temperature, and chain of custody.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
NEWSLETTER ARCHIVE
- 02.27.26 -- Optimize Your Cell And Gene Therapy Manufacturing Workflows
- 02.27.26 -- Active Versus Passive Shipping Solutions For Clinical Shipments
- 02.26.26 -- January 2026 — CDMO Opportunities And Threats Report
- 02.26.26 -- Unlocking Reliability And Speed In CGT
- 02.25.26 -- Securing And Strengthening Workflows From Design To Delivery
- Powering AI And Synthetic Biology In Therapy Design
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections